S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
His system isolated NVIDIA - Here's His Next Buy. (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
BREAKING: The truth about war with China (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
His system isolated NVIDIA - Here's His Next Buy. (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
BREAKING: The truth about war with China (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
His system isolated NVIDIA - Here's His Next Buy. (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
BREAKING: The truth about war with China (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
His system isolated NVIDIA - Here's His Next Buy. (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
BREAKING: The truth about war with China (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
NASDAQ:AKTS

Akoustis Technologies (AKTS) Stock Forecast, Price & News

$0.76
-0.02 (-2.58%)
(As of 09/26/2023 ET)
Compare
Today's Range
$0.75
$0.79
50-Day Range
$0.74
$2.57
52-Week Range
$0.70
$4.96
Volume
770,567 shs
Average Volume
773,606 shs
Market Capitalization
$54.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.92

Akoustis Technologies MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
418.4% Upside
$3.92 Price Target
Short Interest
Bearish
9.98% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$22,877 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.59) to ($0.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Computer And Technology Sector

435th out of 581 stocks

Telephone & Telegraph Apparatus Industry

7th out of 11 stocks


AKTS stock logo

About Akoustis Technologies (NASDAQ:AKTS) Stock

Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., designs, develops, manufactures, and sells radio frequency (RF) filter products for the mobile wireless device industry in the United States, Asia, Europe, and internationally. It operates through two segments, Foundry Fabrication Services and RF Filters. The Foundry Fabrication Services segment provides engineering review services and microelectromechanical systems foundry services. The RF Filters segment sells amplifier and filter products. It offers RF filters for mobile wireless devices, such as smartphones and tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, and military and defense applications. Akoustis Technologies, Inc. was founded in 2013 and is headquartered in Huntersville, North Carolina.

AKTS Price History

AKTS Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Akoustis Technologies Shares Drop on Weak 4Q Results
Roth MKM Remains a Buy on Akoustis Technologies (AKTS)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Craig-Hallum Sticks to Its Buy Rating for Akoustis Technologies (AKTS)
Earnings Outlook For Akoustis Technologies
AKTS - Akoustis Technologies, Inc.
Akoustis Technologies (NASDAQ: AKTS)
See More Headlines
Receive AKTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akoustis Technologies and its competitors with MarketBeat's FREE daily newsletter.

AKTS Company Calendar

Last Earnings
9/06/2023
Today
9/26/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Industry
Telephone & telegraph apparatus
Sub-Industry
N/A
Current Symbol
NASDAQ:AKTS
Fax
N/A
Employees
205
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.92
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$1.75
Forecasted Upside/Downside
+407.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-63,560,000.00
Net Margins
-234.35%
Pretax Margin
-243.37%

Debt

Sales & Book Value

Annual Sales
$27.12 million
Book Value
$1.20 per share

Miscellaneous

Free Float
68,303,000
Market Cap
$55.84 million
Optionable
Not Optionable
Beta
1.66
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Jeffrey B. ShealyMr. Jeffrey B. Shealy (Age 54)
    Founder, Pres, CEO & Director
    Comp: $740.01k
  • Mr. Kenneth E. BollerMr. Kenneth E. Boller (Age 52)
    CFO & Corp. Controller
    Comp: $279.91k
  • Mr. David M. AicheleMr. David M. Aichele (Age 57)
    Exec. VP of Bus. Devel.
    Comp: $329.4k
  • Mr. Thomas Andrew Sepenzis (Age 51)
    VP of Corp. Devel. & IR
  • Mr. Andrew Wright
    Gen. Counsel & Corp. Sec.
  • Ms. Mary Winters
    Exec. VP of Fab & Corp. Operations
  • Mr. Kamran Cheema
    Chief Product Officer













AKTS Stock - Frequently Asked Questions

Should I buy or sell Akoustis Technologies stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akoustis Technologies in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AKTS shares.
View AKTS analyst ratings
or view top-rated stocks.

What is Akoustis Technologies' stock price forecast for 2023?

2 equities research analysts have issued twelve-month price objectives for Akoustis Technologies' stock. Their AKTS share price forecasts range from $1.75 to $7.00. On average, they predict the company's stock price to reach $3.92 in the next year. This suggests a possible upside of 407.5% from the stock's current price.
View analysts price targets for AKTS
or view top-rated stocks among Wall Street analysts.

How have AKTS shares performed in 2023?

Akoustis Technologies' stock was trading at $2.82 at the start of the year. Since then, AKTS stock has decreased by 72.6% and is now trading at $0.7717.
View the best growth stocks for 2023 here
.

Are investors shorting Akoustis Technologies?

Akoustis Technologies saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 7,220,000 shares, an increase of 9.7% from the August 15th total of 6,580,000 shares. Based on an average trading volume of 844,600 shares, the short-interest ratio is presently 8.5 days.
View Akoustis Technologies' Short Interest
.

When is Akoustis Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our AKTS earnings forecast
.

How were Akoustis Technologies' earnings last quarter?

Akoustis Technologies, Inc. (NASDAQ:AKTS) released its earnings results on Wednesday, September, 6th. The technology company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.05. The technology company had revenue of $8.33 million for the quarter, compared to analysts' expectations of $8.40 million. Akoustis Technologies had a negative trailing twelve-month return on equity of 63.41% and a negative net margin of 234.35%. During the same quarter in the prior year, the company earned ($0.26) earnings per share.

What guidance has Akoustis Technologies issued on next quarter's earnings?

Akoustis Technologies updated its first quarter 2024 earnings guidance on Thursday, September, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $7.08 million-$7.08 million, compared to the consensus revenue estimate of $7.66 million.

What other stocks do shareholders of Akoustis Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akoustis Technologies investors own include Inseego (INSG), NVIDIA (NVDA), Block (SQ), Editas Medicine (EDIT), Marvell Technology (MRVL), Alibaba Group (BABA), Invitae (NVTA), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP) and JD.com (JD).

What is Akoustis Technologies' stock symbol?

Akoustis Technologies trades on the NASDAQ under the ticker symbol "AKTS."

Who are Akoustis Technologies' major shareholders?

Akoustis Technologies' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.68%), Silverback Asset Management LLC (2.85%), Silverback Asset Management LLC (2.85%), Geode Capital Management LLC (1.98%), Sargent Investment Group LLC (1.91%) and Granahan Investment Management LLC (1.81%). Insiders that own company stock include Arthur Geiss, David Aichele, James Michael Mcguire, Jeffrey B Shealy, Jeffrey B Shealy, Jeffrey Mcmahon, Kenneth Boller, Rohan Houlden, Steven Denbaars and Suzanne B Rudy.
View institutional ownership trends
.

How do I buy shares of Akoustis Technologies?

Shares of AKTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akoustis Technologies' stock price today?

One share of AKTS stock can currently be purchased for approximately $0.77.

How much money does Akoustis Technologies make?

Akoustis Technologies (NASDAQ:AKTS) has a market capitalization of $55.84 million and generates $27.12 million in revenue each year. The technology company earns $-63,560,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.

How many employees does Akoustis Technologies have?

The company employs 205 workers across the globe.

How can I contact Akoustis Technologies?

Akoustis Technologies' mailing address is 9805 NORTHCROSS CENTER COURT SUITE A, HUNTERSVILLE NC, 28078. The official website for the company is www.akoustis.com. The technology company can be reached via phone at (704) 997-5735 or via email at bprag@delmarconsulting.com.

This page (NASDAQ:AKTS) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -